Welcome to our dedicated page for OKYO PHARMA SEC filings (Ticker: OKYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pulling the signal from OKYO Pharma’s dense biotech disclosures can feel harder than decoding a clinical protocol. Trial milestones for OK-101, frequent shelf registrations, or sudden 6-K updates on capital raises are scattered across multiple forms. That complexity is why investors searching for “OKYO Pharma SEC filings explained simply” start here.
Stock Titan’s AI reads every page so you don’t have to. Our engine delivers real-time alerts and plain-English highlights the moment an “OKYO Pharma quarterly earnings report 10-Q filing” or 20-F hits EDGAR. The same technology powers side-by-side “OKYO Pharma earnings report filing analysis,” transforming footnotes on R&D spend and cash runway into concise metrics. Need event updates? See “OKYO Pharma 8-K material events explained” (or the company’s 6-K equivalent) within minutes, complete with links to source sections for quick verification.
Staying ahead of management moves is just as seamless. Track “OKYO Pharma insider trading Form 4 transactions” and receive push notifications for “OKYO Pharma Form 4 insider transactions real-time.” Our AI points out patterns in “OKYO Pharma executive stock transactions Form 4,” helping you spot confidence—or concern—before the market reacts.
- “OKYO Pharma annual report 10-K simplified” with AI-generated key takeaways
- Segment-level drill-downs that align R&D expense with OK-101 trial phases
- Direct links to “OKYO Pharma proxy statement executive compensation” details
Whether you’re understanding OKYO Pharma SEC documents with AI for the first time or benchmarking dilution risk against peers, Stock Titan turns every filing into actionable knowledge—without the jargon.
OKYO Pharma (OKYO) reported that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, purchased 82,018 of the company’s ordinary shares on NASDAQ on November 21, 2025.
This additional purchase increases Cerrone’s total beneficial holding to 10,464,695 shares. The disclosure is informational in nature and does not change the company’s capital structure or operations, but it highlights further share accumulation by a key insider.
OKYO Pharma LTD reported that its Chief Executive Officer, Gary S. Jacob, Ph.D., will present at the Ophthalmology Innovation Summit (OIS) XV. His presentation is scheduled for November 22, 2025, from 8:30–9:30 AM PT in the “Anterior Innovation Showcase” session. OIS XV, held November 21–22, 2025, at the San Diego Marriott Marquis & Marina, is described as a premier annual event that brings together innovators, investors, executives, and clinicians in eye care. The summit focuses on anterior and posterior segment advances through panel discussions, company showcases, and partnering meetings, highlighting OKYO Pharma’s participation in a global forum dedicated to treatments for vision-threatening conditions.
OKYO Pharma (OKYO) filed a Form 6-K announcing that Chief Executive Officer Gary S. Jacob, Ph.D., will present at the 33rd Annual BIO-Europe partnering conference in Vienna, Austria.
The related news announcement is furnished as Exhibit 99.1. The company states this exhibit is furnished and not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
OKYO Pharma reported that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 210,000 of the company’s ordinary shares on NASDAQ. Following this purchase, his total holding is 10,382,677 shares. The news announcement was furnished as Exhibit 99.1 and is not deemed filed under Section 18 of the Exchange Act.
OKYO Pharma Limited filed an Amendment No. 1 to its Form 20-F for the fiscal year ended March 31, 2025 to correct an omission in the exhibits. The sole change is a revision of the Exhibit Table to include the Company’s Clawback Policy, which had been erroneously omitted from the original filing. The amendment states that no other disclosures were modified or updated and that subsequent events after the original filing are not reflected.
The filing confirms the registrant is incorporated in Guernsey, prepares financial statements under IFRS, is an emerging growth company, is listed on the NASDAQ Capital Market, and had 37,610,676 ordinary shares outstanding as of July 3, 2025. The company indicates it has filed required reports and submitted required interactive data files.
FAQ
What is the current stock price of OKYO PHARMA (OKYO)?
What is the market cap of OKYO PHARMA (OKYO)?
